No Data
No Data
Buy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal Trial
Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate
Express News | Regulus Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $95.9 Mln; Cash Runway Into H1 2026
Regulus Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Express News | Regulus Therapeutics Q2 Operating Expenses USD 12.26 Million
No Data
Jenna Ragan : RIGL!! RIGL!!![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Trytosaveabit OP Jenna Ragan : Hehehe! Yes ma’am pretty lady! I just knew that one would get you attention! Hehehe. Thanks for the smile you just gave me! Hehehe![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Jenna Ragan Trytosaveabit OP : You are very welcome![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Seraphicall : CMMB yes.
but you have these many holdings?
MARKET-TEST-DUMMY : I want to say thank you because it takes time to research this information. Your very kind for sharing.
A true gentleman and scholar!
View more comments...